2 ‘hidden’ healthcare stocks I would buy and hold

These two healthcare stocks may be under the radar, but I believe they could bring great returns.

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The healthcare sector can be a very lucrative market to invest in, but it can also be incredibly hard to predict. The two healthcare stocks I’m going to talk about today have a relatively low profile despite their attractive offerings, which I believe is a good thing. 

I would buy these two stocks and hold them for the long term in order to reap the rewards that they could potentially offer.

Breathe easy

Vectura Group (LSE: VEC) develops respiratory products for asthma and smokers cough, which is actually one of the leading causes of death worldwide. Vectura is a global leader in this sector with a strong track record. For example, the company’s technology is used in half of the new inhalers launched from 2012 to 2016, showing how it has made a major impact on the market.

Furthermore, it got a big boost in May after winning a patent battle with healthcare giant GlaxoSmithKline. The company was awarded $89.7m when it was proved that GSK’s inhalers infringed on its patents. Shares in Vectura jumped 11% in May to 80.2p and have since only slightly dropped to around 79p at the time of writing.

Analysts predict that VEC will grow in terms of income 67% year-on-year which is an extremely promising outlook. The company is expected by analysts to break even by 2020, making a profit of £12m by 2021. I would consider investing now, to reap the rewards this company could offer in later years.

Moreover, the smart inhaler technology market is booming at the moment as pharmaceutical companies aim to focus on and push digital health. Vectura is one of the leading companies looking to develop more of this technology. With rising demand, it’s easy to see how Vectura should continue to grow and why I would consider investing.

Supporting the healthcare market

UDG Healthcare (LSE: UDG) helps pharmaceutical companies get their products to the market, providing packaging, transportation and education. Essentially, the company provides services that allow pharmaceutical companies to focus on their main business while outsourcing services to UDG. Services being outsourced is a major trend in the healthcare market and one that UDG is poised to continue benefiting from.

Its shares surged in May after it acquired two UK and US consultancy businesses for $106m. These acquisitions should boost growth at the company, giving it a wider reach and more clients for which it can provide its services. Acquisition is a key strategy for UDG: since 2012, it has acquired 21 companies and doesn’t show any signs of slowing down.

With a share price of 705p at the time of writing, a dividend yield of 1.8%, and analyst predictions of UDG’s earnings per share rising by 5% this year, it certainly seems to have potential. The yield may be lower than most of us would like, but its future potential (and its past performance) are enough for me to believe that this stock is worth the investment, especially as more and more pharmaceutical companies seem to be looking to outsource the services that UDG is ready to provide.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

fional has no position in any of the shares mentioned. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. The Motley Fool UK has recommended UDG Healthcare. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Up 26%, can the BT share price really push higher still?

The BT share price has surged on several catalysts in 2024, but there’s evidence to suggest that the stock could…

Read more »

Man writing 'now' having crossed out 'later', 'tomorrow' and 'next week'
Investing Articles

What are the best dividend shares to buy right now?

As shares in B&M European Value Retail have fallen, the dividend yield has reached a 10-year high. Should investors be…

Read more »

Surprised Black girl holding teddy bear toy on Christmas
Investing Articles

My favourite FTSE 100 passive income stock that keeps the Christmas coffers full

The holiday season is expensive and can leave many consumers struggling to make ends meet. Here’s how I use a…

Read more »

Investing Articles

The latest growth forecasts suggest the Glencore share price will hit 555p!

Harvey Jones has been disappointed by the performance of the Glencore share price since he bought the commodity stock last…

Read more »

Dividend Shares

A closer look at the 11% dividend yield forecast for Phoenix Group shares

Phoenix Group shares have one of the highest dividend yields in the FTSE 100 index today. Could this be a…

Read more »

Investing Articles

If I’d put £25,000 into the FTSE 350 at the start of 2024, here’s how much I’d have today!

Many FTSE shares have rebounded this year as interest rates look set to keep heading lower and market appetite for…

Read more »

Investing Articles

Up 40%, but experts forecast the easyJet share price could soon hit 664p! Time to buy?

The easyJet share price has been flying lately and stock analysts are predicting more fun to come. But there's only…

Read more »

Storytelling image of a multiethnic senior couple in love - Elderly married couple dating outdoors, love emotions and feelings
Investing Articles

Worried about tax raids? Here’s how I’m targeting a £44,526 passive income with shares

Investing in a Self-Invested Personal Pension (SIPP) or Individual Savings Account (ISA) can supercharge one's passive income, says Royston Wild.

Read more »